Cardiovascular Disease (CVD) in Europe causes 3.9m deaths and over 1.8m deaths in the EU. The European Society for Cardiology (ESC) estimates the EU cost to be over €196 billion per year. Currently CVD monitoring includes a hospital attendance, cardio measurement by a 12 lead ‘wet’ (ECG) and follow-up with a doctor. This process is time-consuming, costly to health systems and at best provides a snapshot of a patient’s heart health. If the results are an inconclusive ECG, a doctor may prescribe a Holter (24-48hrs), Event (1-2 months) or longer term mobile cardiac telemetry (MCT) monitors. However, current monitoring has a number of negative factors associated with usage eg.discomfort inhibit sleep and limit patient activities all adversely impacting uptake, reliability and, critically, accuracy of results. Additional problems associated with the elderly and infirm, i.e. dementia, delicate skin, sleep problems and difficulties in attending clinics, creates acceptance problems. With further R&D following this feasibility study, SmartLife’s’ objective is to prove the viability of its Wellwatch device and develop the solution to be the first certified medical wearable garment monitoring a patient’s condition in real-time, in the comfort of their own home, complying with their lifestyles whilst having no extraneous tech wires, fluids or straps.